

PATIENT INFORMATION				COVERAGE TYPE
PATIENT LAST NAME	FIRST NAME	INITIAL		<input type="checkbox"/> Alberta Blue Cross <input type="checkbox"/> Alberta Human Services <input type="checkbox"/> Other
DATE OF BIRTH (YYYY/MM/DD)	ALBERTA PERSONAL HEALTH NUMBER			
STREET ADDRESS	CITY	PROV	POSTAL CODE	ID/CLIENT/COVERAGE NUMBER

PRESCRIBER INFORMATION				
PRESCRIBER LAST NAME	FIRST NAME	INITIAL	PRESCRIBER PROFESSIONAL ASSOCIATION REGISTRATION	
STREET ADDRESS			<input type="checkbox"/> CPSA	<input type="checkbox"/> ACO
			<input type="checkbox"/> CARNA	<input type="checkbox"/> ADA+C
CITY , PROVINCE			<input type="checkbox"/> ACP	<input type="checkbox"/> Other
POSTAL CODE			PHONE	FAX
FAX NUMBER MUST BE PROVIDED WITH EACH REQUEST SUBMITTED				

Indicate drug requested (check one box):  Montelukast 5mg + 10mg (e.g. Singulair)  Zafirlukast 20mg (e.g. Accolate)

**Criteria for Coverage of MONTELUKAST / ZAFIRLUKAST**

For the prophylaxis and chronic treatment of asthma in patients over the age of 18 who meet one of the following criteria:  
 a) when used as adjunctive therapy in patients who do not respond adequately to high doses of inhaled glucocorticosteroids and long-acting beta 2 agonists. Patients must be unable to use long-acting beta 2 agonists or have demonstrated persistent symptoms while on long-acting beta 2 agonists, OR  
 b) cannot operate inhaler devices.

For the prophylaxis of exercise-induced bronchoconstriction in patients over the age of 18 where tachyphylaxis exists for long-acting beta 2 agonists.

Special Authorization for both criteria may be granted for six months. This product is eligible for auto-renewal.

**Note:** Refer to the Alberta Drug Benefit List for Restricted Benefit coverage of patients two to 18 years of age inclusive for Montelukast and 12 to 18 years of age inclusive for Zafirlukast.

**Please provide the following information for NEW requests (Section 1 and Section 2 or 3 must be completed)**

**Section 1: Indication**

Prophylaxis and chronic treatment of asthma (If yes, proceed to Section 2A or 2B only)  
 Prophylaxis of exercise-induced bronchoconstriction (If yes, proceed to Section 3 only)  
 Other (please specify) \_\_\_\_\_

**Section 2: Prophylaxis and chronic treatment of asthma**

<p><b>A. Previous Medication Use</b></p> <p>a) Please indicate if an inhaled glucocorticosteroid was used  <input type="checkbox"/> Yes <input type="checkbox"/> No (If no, please specify reason) _____</p> <p>b) Please indicate if a long-acting beta 2 agonist (e.g. salmeterol or formoterol) was tried  <input type="checkbox"/> Yes → Response: <input type="checkbox"/> Persistent symptoms  <input type="checkbox"/> Other (please specify) _____  <input type="checkbox"/> No (If no please specify) _____</p>	<p><b>B. Use of Inhaler Device</b></p> <p>Please indicate if the patient has difficulty using an inhaler device:  <input type="checkbox"/> Yes (Please elaborate on the nature of the difficulty) _____  <input type="checkbox"/> No</p>
--	--

**Section 3: Prophylaxis of exercise induced bronchoconstriction**

Does this patient have tachyphylaxis with long-acting beta 2 agonists?  Yes  No  Other (please specify) \_\_\_\_\_

**Additional information relating to request**

PRESCRIBER'S SIGNATURE	DATE	Please forward this request to <b>Alberta Blue Cross, Clinical Drug Services</b> <b>10009 108 Street NW, Edmonton, Alberta T5J 3C5</b> <b>FAX: 780-498-8384 in Edmonton • 1-877-828-4106 toll free all other areas</b>
------------------------	------	---

**ONCE YOUR REQUEST HAS SUCCESSFULLY TRANSMITTED, PLEASE DO NOT MAIL OR RE-FAX YOUR REQUEST**